Background Understanding interindividual variability in medication dosing is central to precision medicine. Despite significant pharmacogenomic (PGx) insights into key biological pathways influencing drug response, the polygenic contribution to dose variability and the potential of electronic health records for maintenance dose estimation remain largely unexplored. Methods We leveraged longitudinal drug purchase data linked to the Estonian Biobank (N = 212,000) to derive individual-level daily doses per purchase as well as median and maximum doses as consolidated metrics across purchases for cardiovascular and psychiatric drugs: statins, warfarin, metoprolol, antidepressants, and antipsychotics. Associations with polygenic scores (PGSs) for 16 traits were assessed using linear mixed models and multivariable regression with a forward stepwise approach. Genome-wide association studies (GWAS) were followed by gene set enrichment analyses for known PGx genes. Results Sample sizes ranged from 684 (antipsychotics) to 20,642 (statins), with median doses reflecting typical maintenance doses. Trait-specific PGSs were significant for the daily dose of statins (coronary heart disease PGS, β = 0.02, P = 5.9 × 10–10) and metoprolol (systolic blood pressure PGS, β = 0.03, P = 7.5 × 10–13). The PGS for body mass index was linked to daily doses of statins (β = 0.02, P = 6.4 × 10–7), metoprolol (β = 0.03, P = 1.4 × 10–14), and warfarin (β = 0.03, P = 0.001), whereas the PGS for educational attainment showed opposing associations with statins (β = − 0.01, P = 5.9 × 10–4) and antidepressants (β = 0.01, P = 0.002). Median and maximum doses yielded similar, though generally weaker, associations. GWAS confirmed signals for metoprolol (CYP2D6, P = 1.1 × 10–20) and warfarin (CYP2C9, P = 8.9 × 10–60; VKORC1, P = 4.2 × 10–148), as well as enrichment of PGx signals for individual statins (P = 0.02 for simvastatin, P = 0.03 for atorvastatin). Associations remained significant after adjusting for disease-specific PGSs, suggesting independent contributions of PGx loci. Conclusions These findings illustrate the feasibility and value of leveraging real-world electronic health records to derive pharmacologically meaningful medication dosing phenotypes. Both polygenic and pharmacogenomic signals contribute to dose variability, underscoring their potential utility in personalized prescribing strategies.

Polygenic and pharmacogenomic contributions to medication dosing: a real-world longitudinal biobank study

期刊论文
出版模式：

开放获取
发表日期：

2025年7月2日

查看全文

Silva Kasela,
Laura Birgit Luitva,
Kristi Krebs,
Märt Möls,
Lili Milani,
Maris Alver

摘要

Background

Understanding interindividual variability in medication dosing is central to precision medicine. Despite significant pharmacogenomic (PGx) insights into key biological pathways influencing drug response, the polygenic contribution to dose variability and the potential of electronic health records for maintenance dose estimation remain largely unexplored.

Methods

We leveraged longitudinal drug purchase data linked to the Estonian Biobank (N = 212,000) to derive individual-level daily doses per purchase as well as median and maximum doses as consolidated metrics across purchases for cardiovascular and psychiatric drugs: statins, warfarin, metoprolol, antidepressants, and antipsychotics. Associations with polygenic scores (PGSs) for 16 traits were assessed using linear mixed models and multivariable regression with a forward stepwise approach. Genome-wide association studies (GWAS) were followed by gene set enrichment analyses for known PGx genes.

Results

Sample sizes ranged from 684 (antipsychotics) to 20,642 (statins), with median doses reflecting typical maintenance doses. Trait-specific PGSs were significant for the daily dose of statins (coronary heart disease PGS, β = 0.02, P = 5.9 × 10^–10) and metoprolol (systolic blood pressure PGS, β = 0.03, P = 7.5 × 10^–13). The PGS for body mass index was linked to daily doses of statins (β = 0.02, P = 6.4 × 10^–7), metoprolol (β = 0.03, P = 1.4 × 10^–14), and warfarin (β = 0.03, P = 0.001), whereas the PGS for educational attainment showed opposing associations with statins (β = − 0.01, P = 5.9 × 10^–4) and antidepressants (β = 0.01, P = 0.002). Median and maximum doses yielded similar, though generally weaker, associations. GWAS confirmed signals for metoprolol (CYP2D6, P = 1.1 × 10^–20) and warfarin (CYP2C9, P = 8.9 × 10^–60; VKORC1, P = 4.2 × 10^–148), as well as enrichment of PGx signals for individual statins (P = 0.02 for simvastatin, P = 0.03 for atorvastatin). Associations remained significant after adjusting for disease-specific PGSs, suggesting independent contributions of PGx loci.

Conclusions

These findings illustrate the feasibility and value of leveraging real-world electronic health records to derive pharmacologically meaningful medication dosing phenotypes. Both polygenic and pharmacogenomic signals contribute to dose variability, underscoring their potential utility in personalized prescribing strategies.